ASCO GU 2017 Bladder Cancer

Viewing 1-20 of 20 articles

ASCO GU 2017: Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. - Session Highlights

ASCO GU 2017: BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer - Session Highlights

ASCO GU 2017: Resection margins after radical cystectomy at academic versus community cancer centers. - Session Highlights

ASCO GU 2017: Characterizing the costs of complications after cystectomy: Can we target the primary drivers? - Session Highlights

ASCO GU 2017: Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. - Session Highlights

ASCO GU 2017: Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer - Session Highlights

ASCO GU 2017: Quality of care in non-muscle invasive bladder cancer: optimizing surgical and medical therapies - Session Highlights

ASCO GU 2017: Intravesical rAD-IFNa/Syn3 for patients with high-grade, Bacillus Calmette-Guerin (BCG) refractory or relapsed non-muscle invasive bladder cancer: a phase II randomized study - Session Highlights

ASCO GU 2017: Options for the Patient Who Does Not Respond to Bacillus Calmette-Guérin When Radical Cystectomy Is Not an Option - Session Highlights

ASCO GU 2017: Barriers in Progress in Muscle-Invasive and Non-muscle Invasive Bladder Cancer - Oncology Perspective - Session Highlights

ASCO GU 2017: Barriers in Progress in Muscle-Invasive and Non-muscle Invasive Bladder Cancer - Urology Perspective - Session Highlights

ASCO GU 2017: Barriers in Progress in Muscle-Invasive and Non-muscle Invasive Bladder Cancer - Session Highlights

ASCO GU 2017: Urothelial Carcinoma: Year in Review - Session Highlights

ASCO GU 2017: Keynote Lecture, Emerging Impact of Genomics on the Clinical Management of Bladder Cancer - Session Highlights

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Urologist View - Session Highlights

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Medical Oncologist’s Perspective - Session Highlights

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Surgeon’s Perspective - Session Highlights

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Urologist Perspective - Session Highlights

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Radiation Oncology Perspective - Session Highlights

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Session Highlights